Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 485732, 5 pages
http://dx.doi.org/10.1155/2015/485732
Research Article

Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation

1Radiation Therapy Oncology Unit, Second Department of Radiology, University Hospital of Athens “ATTIKON”, Rimini 1, Haidari, 124 64 Athens, Greece
2Oncology Clinic, 401 General Military Hospital, Mesogeion 138 & Katehaki, 115 25 Athens, Greece
3Department of Radiotherapy, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41110 Larissa, Greece
4Pammakaristos General Hospital, Iakovaton 43, 11144 Athens, Greece
5Radiation Therapy Oncology Department, First Department of Radiology, Aretaieion Hospital, University of Athens Medical School, Vassilissis Sofias 76, 115 28 Athens, Greece
6Biochemistry Department, 401 General Military Hospital, Mesogeion 138 & Katehaki, 115 25 Athens, Greece
7Oncology Clinic, University Hospital of Athens “ATTIKON”, Rimini 1, Haidari, 124 64 Athens, Greece
8Radiation Oncology Clinic, University Hospital of Thessaloniki AHEPA, 1 Street Kyriakidi, 54636 Thessaloniki, Greece

Received 9 September 2014; Revised 9 March 2015; Accepted 12 March 2015

Academic Editor: Olive Joy Wolfe

Copyright © 2015 Maria Tolia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Y. Paik, I. K. Lee, Y. S. Lee, N. Y. Sung, and T. S. Kwon, “Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients,” Cancer Research and Treatment, vol. 46, no. 1, pp. 65–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. W. Kamp, E. Shacter, and S. A. Weitzman, “Chronic inflammation and cancer: the role of the mitochondria,” Oncology, vol. 25, no. 5, pp. 400–413, 2011. View at Google Scholar · View at Scopus
  4. J. P. F. H. A. Simons, A. M. W. J. Schols, W. A. Buurman, and E. F. M. Wouters, “Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones,” Clinical Science, vol. 97, no. 2, pp. 215–223, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Van Leeuwen and M. H. Van Rijswijk, “Acute phase proteins in the monitoring of inflammatory disorders,” Bailliere's Clinical Rheumatology, vol. 8, no. 3, pp. 531–552, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. ICRU, “Prescribing, recording and reporting photon beam therapy 1993,” ICRU Report 50, 62, 1999. View at Google Scholar
  7. L. B. Marks, E. d. Yorke, A. Jackson et al., “Use of normal tissue complication probability models in the clinic,” International Journal of Radiation Oncology, Biology, Physics, vol. 76, pp. 10–19, 2010. View at Google Scholar
  8. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer, 2009, http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf.
  9. “National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non Small Cell Lung Cancer,” http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf.
  10. H. R. Scott, D. C. McMillan, L. M. Forrest, D. J. F. Brown, C. S. McArdle, and R. Milroy, “The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer,” British Journal of Cancer, vol. 87, no. 3, pp. 264–267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. C. McMillan, M. M. Elahi, N. Sattar, W. J. Angerson, J. Johnstone, and C. S. McArdle, “Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer,” Nutrition and Cancer, vol. 41, no. 1-2, pp. 64–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Siemes, L. E. Visser, J.-W. W. Coebergh et al., “C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5216–5222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. H. Allin and B. G. Nordestgaard, “Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 48, no. 4, pp. 155–170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. S. D. Roxburgh and D. C. McMillan, “Role of systemic inflammatory response in predicting survival in patients with primary operable cancer,” Future Oncology, vol. 6, no. 1, pp. 149–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. O'Dowd, L. A. McRae, D. C. McMillan, A. Kirk, and R. Milroy, “Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 7, pp. 988–992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. T. G. Maria, K. E. Vasileios, P. S. Panagiotis, and S. N. Kostas, “Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy,” International Journal of Clinical and Experimental Medicine, vol. 6, no. 1, pp. 50–56, 2013. View at Google Scholar · View at Scopus
  17. S. R. Pine, L. E. Mechanic, L. Enewold et al., “Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer,” Journal of the National Cancer Institute, vol. 103, no. 14, pp. 1112–1122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Xu, M. Zhu, Y. Du et al., “Serum C-reactive protein and risk of lung cancer: a case-control study,” Medical Oncology, vol. 30, no. 1, article 319, 2013. View at Publisher · View at Google Scholar
  19. B. Tulek, H. Koylu, F. Kanat, U. Arslan, and F. Ozer, “Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients,” Contemporary Oncology, vol. 17, no. 1, pp. 68–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. A. Higgins, J. P. Chino, N. Ready et al., “Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy,” Journal of Thoracic Oncology, vol. 7, no. 7, pp. 1141–1147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Jin, L. Zhao, and F. Peng, “Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer,” Clinics, vol. 68, no. 5, pp. 686–693, 2013. View at Publisher · View at Google Scholar · View at Scopus